Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer

@article{Burris2018RibociclibFT,
  title={Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer},
  author={H. Burris},
  journal={Expert Review of Anticancer Therapy},
  year={2018},
  volume={18},
  pages={201 - 213}
}
  • H. Burris
  • Published 2018
  • Medicine
  • Expert Review of Anticancer Therapy
    • ABSTRACT Introduction: The emergence of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors marked a significant advancement in the treatment of advanced breast cancer. Ribociclib is an orally bioavailable, highly selective inhibitor of CDK4/6. In combination with various endocrine therapies, ribociclib has demonstrated clinical activity as a first-line therapy for patients with HR+, HER2− advanced breast cancer, without compromising the favorable toxicity profile associated with endocrine… CONTINUE READING
    View on Taylor & Francis
    ncbi.nlm.nih.gov
    6 Citations
    Background Citations
    1
    6 Citations
    Citation Type

    Citation Type

    Abemaciclib, a third CDK 4/6 inhibitor for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.
    Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma
    • 13
    An oncoinformatics study to predict the inhibitory potential of recent FDA-approved anti-cancer drugs against human Polo-like kinase 1 enzyme: a step towards dual-target cancer medication
    Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer
    • 7
    • PDF
    Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib.
    • 19
    “Energetic” Cancer Stem Cells (e-CSCs): A New Hyper-Metabolic and Proliferative Tumor Cell Phenotype, Driven by Mitochondrial Energy
    • 24
    • PDF

    References

    SHOWING 1-10 OF 114 REFERENCES
    Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer
    • 12
    Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
    • 601
    • PDF
    Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
    • 1,546
    • PDF
    Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.
    • 67
    • Highly Influential
    Abstract CT045: Ribociclib + letrozole for first-line treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): efficacy by baseline tumor markers
    • 7
    Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.
    • 260
    • Highly Influential
    • PDF
    Abstract P4-22-18: Phase Ib safety, efficacy, and molecular analysis of ribociclib (LEE011) plus letrozole for the treatment of ER+, HER2– advanced breast cancer
    • 4
    The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
    • 1,119
    • PDF
    MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
    • M. Goetz, M. Toi, +15 authors A. Di Leo
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2017
    • 452
    • Highly Influential
    Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
    • 144